SCHEDULE 13G: Voss Capital and Affiliates Disclose 5.6% Passive Stake in Rein Therapeutics

Voss Capital, along with its affiliated funds and managing member Travis W. Cocke, has disclosed a combined beneficial ownership of 5.6% of Rein Therapeutics, Inc.'s common stock.

Summary

• Voss Capital, LP and Travis W. Cocke, its managing member, collectively reported beneficial ownership of 1,277,856 shares of Rein Therapeutics, Inc. common stock, representing approximately 5.6% of the outstanding class.
• Voss Advisors GP, LLC, as the general partner for two affiliated funds, beneficially owns 899,974 shares, or 3.9% of the outstanding shares.
• Voss Value Master Fund, LP holds 583,206 shares, equating to 2.5% beneficial ownership.
• Voss Value-Oriented Special Situations Fund, LP holds 316,768 shares, equating to 1.4% beneficial ownership.
• The reported percentages are based on a total of 22,895,316 shares outstanding, which includes 21,992,387 shares as of March 27, 2025, plus 159,500 shares from 2023 warrant exercises and 743,429 shares from 2024 warrant exercises.
• The filing indicates that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a standard disclosure required when an investor or group acquires beneficial ownership exceeding 5% of a company's outstanding shares. It provides transparency regarding significant ownership stakes, which can sometimes signal investor confidence or potential future engagement, though this filing explicitly states a passive intent with a carve-out for director nominations.

Stakeholder Impact

• Shareholders: The disclosure of a significant 5.6% stake by Voss Capital and its affiliates provides transparency regarding a notable institutional investor's position in Rein Therapeutics. While stated as passive, the inclusion of a carve-out for director nominations under Rule 14a-11 suggests a potential for future engagement in corporate governance, which could influence shareholder value.

Key Dates

Keywords

Rein Therapeutics, Voss Capital, Travis W. Cocke, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Shareholder Disclosure